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A lightweight measuring device
for the continuous in vivo
monitoring of glucose 
by means of 
ultraslow microdialysis in
combination with a miniaturised
flow-through biosensor
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Summary
A lightweight measuring device for continuous in vivo monitoring of glucose in
biological compartments is presented. The measuring device consists of a
miniaturised flow-through biosensor, connected to a microdialysis probe and a
semi-vacuum pump.The biosensor is based on the amperometric detection of
hydrogen peroxide after conversion of glucose by immobilised glucose oxidase.
A portable potentiostat equipped with data logging is used for detection and
registration. The device is validated for its accuracy, precision, linearity,
selectivity and stability during ex vivo and in vivo experiments. The accuracy
was found to be well in accordance with the criteria set for methods of Self
Monitoring of Blood Glucose for patients with diabetes mellitus. In vivo
monitoring of glucose in dialysate of subcutaneous sampled tissue during
glucose tolerance tests in healthy volunteers demonstrates the potential of this
measuring device.
7.1 Introduction
Diabetes mellitus is a chronic disorder characterised by insulin deficiency, hyperglycaemia
and a high risk of the development of irreversible damage to eyes, kidneys, peripheral
nerves, heart and blood vessels1,2.A long-term study performed by the Diabetes Control
and Complications Trial Research Group3 has conclusively demonstrated that if glucose
levels are tightly regulated diabetic complications are reduced. In addition, hypoglycaemic
events can be prevented. In practice, blood glucose levels are controlled with the finger-
prick method.The measurements thus obtained however are limited and inform only about
the blood glucose levels at intermittent moments. Continuous in vivo glucose monitoring
may therefore be a significant improvement. For this reason, throughout the years elaborate
research efforts have been devoted to the development of a glucose sensor4. Biosensors
may not only offer a viable route for continuous real-time glucose monitoring carried out
by clinical laboratories at the patient’s bedside or during operations but also for self
monitoring at home5. An ideal biosensor has many advantages over conventional analysis
such as reagentless analysis and independence of laboratory facilities. Several investigators
reported the use of a peroxide based needle-type amperometric biosensor, that can be
easily manufactured and miniaturised.To avoid thromboembolism and complications arising
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from surface fouling of the electrode by proteins and coagulation composites (e.g.
fibrinogen/fibrin, platelets, leukocytes and red cells), the needle-type glucose sensor was
most often inserted in the subcutaneous tissue6-12. As an alternative to implanted needle
glucose biosensors, microdialysis (MD) and/or ultrafiltration (UF)13-24 as a sampling
interface between the body and the biosensor have been proposed.These techniques are
regarded as minimally invasive because the needles required for the insertion of the MD or
UF probe are relatively small25. And although the effect of probe implantation on the
glucose measurements is still a matter of concern, these sampling techniques have
demonstrated an improvement of the stability and reliability of the biosensors tested thus
far26,27.The sampling principle of MD is based on diffusion down the concentration gradient
existing between the perfusion fluid (dialysate) and the outside environment of the semi-
permeable membrane (interstitial fluid). Small analytes, such as glucose, are perfused
whereas the semi-permeable membrane excludes cells and/or large molecules.A relatively
clean matrix is obtained which is transported by pumping and analysed outside the body
with a glucose biosensor.A major drawback of conventional MD is that the concentration
of glucose is always lower in the dialysate than in the sampled interstitial fluid, and excessive
(in vivo) calibration procedures are required for accurate monitoring28.The in vivo recovery,
the dialysate/interstitial concentration ratio, depends on variables such as probe dimensions
and perfusion flow rate as well as on tissue characteristics as tissue tortuosity, extracellular
volume and metabolism29-31. A generally accepted method for the quantitative analysis of
the interstitial concentration is based on the principle that diffusion of substances from the
interstitial fluids tends to reach equilibrium between dialysate and interstitial
concentrations at extremely low perfusion flow rates32,33. In our laboratory, (near)
quantitative in vivo recoveries have been observed at flow rates of less than 300 nl.min-1
(ultraslow MD)28.To allow, however, continuous in vivo monitoring at these low perfusion
flow rates, the need for a small and low dead volume biosensor was recognised. Because,
to our knowledge, no hardware is yet available to perform in vivo sampling by ultraslow MD
followed by on-line continuous analysis, a portable lightweight measuring device was
developed by us as demonstrated schematically in figure 1.The measuring device comprises
a MD probe, a flow-through biosensor with an internal volume of 10 – 20 nanoliter and a
semi-vacuum pump.The semi-vacuum pump is capable of producing a stable low flow rate
for several days34 and does not need (additional) batteries. A home-made portable
potentiostat equipped with rechargeable battery and a data-logger is used for detection and
registration of the analytical results during monitoring.
In this paper the construction and production of the lightweight portable measuring device
113
Biosensor device and ultraf i l t rat ion sampl ing
proefschrift  30-09-2003  19:53  Pagina 113
are presented.The performance characteristics (precision, selectivity, linearity, accuracy and
stability) of the measuring device, which have been tested in vitro and ex vivo, will be
described. The performance of the measuring device in vivo was assessed with glucose
tolerance tests (OGTT).
7.2 Materials and methods
7.2.1 Materials
The enzyme glucose oxidase from Aspergillus niger (EC 1.1.3.4., grade I) is obtained from
Boehringer Mannheim (Almere, the Netherlands). D(+)-glucose for standard solutions and
1,3-phenylenediamine for the permselective membrane is purchased from Sigma Chemical
Co. (St. Louis, MO).All other chemicals are of pro-analysis quality and are purchased from
E. Merck (Amsterdam, the Netherlands). Double quartz distilled water is used for all





of the instrumental set-up.
proefschrift  30-09-2003  19:53  Pagina 114
to inhibit bacterial growth.The composition of the carrier solution during microdialysis is
a Dulbecco’s buffer phosphate-buffered saline (PBS) (mmol.l-1): NaCl (136.9), KCl (2.7),
KH2PO4 (1.5), CaCl2 (0.9), MgCl2 (0.5), Na2PO4 (8.1) and EDTA (2).The pH is adjusted to
pH 7.4 and purged with helium before use. Standard solutions of glucose are prepared by
diluting the stock solution of glucose (50 mmol.l-1) in PBS and are allowed to reach
mutarotational equilibrium before use (24 hr).
For the construction of the flow-through biosensor, tygon tubing (ID 0.005 inch) is
purchased from Skalar Analytical (Breda, the Netherlands).The auxiliary and work electrode
is made from platinum wire (0.10 mm diameter) whereas the reference electrode is made
from silver wire coated with AgCl (0.125 mm). All these materials are purchased from
Drijfhout (Amsterdam, the Netherlands). Connections with the flow-through biosensor are
made by using fused silica tubing (150 µm OD, 50 µm ID) (Aurora Borealis Control,Assen,
the Netherlands). Connections are glued with cyanoacrylic glue (Henkel, Nieuwegein, the
Netherlands).
During in vitro and in vivo measurements, sampling is performed by means of ultraslow
microdialysis thereby using a CMA 60 microdialysis probe (Aurora Borealis Control,Assen,
the Netherlands).
7.2.2 Production of the flow-through biosensor
By pushing a 0.50 x 16 mm Luer Lock needle (B.Braun, Melsungen, Germany)
perpendicularly through a 0.005 inch ID tygon tubing, consecutively two platinum wires and
a Ag/AgCl wire are placed close to each other into the 0.005 inch ID tygon tubing (see
figure 1). By means of a multi-meter the correct position of the electrodes in the tubing is
checked. Possible leakage formed in the tygon tubing is eliminated with cyanoacrylic glue
(Henkel, Nieuwegein, the Netherlands). The flow-through cell thus prepared is washed
prior to electropolymerisation by connected the cell with a 1 ml syringe (Becton
Dickinson, Etten-Leur, the Netherlands) equipped with a 0.40 x 12 mm Luer Lock needle
(B.Braun, Melsungen, Germany).The flow-through cell as well as the electrodes are washed
by filling the syringe and pushing the following solutions consecutively through the flow-
through cell: methanol (pro analysis, E. Merck, Amsterdam, the Netherlands), 10 %v/v
hydrogen peroxide solution in water (pro analysis, E. Merck,Amsterdam, the Netherlands)
and finally 0.1 M phosphate buffer pH 6.9.After washing the syringe is filled with a solution
containing 2 mg.ml-1 of enzyme and 10 mg.ml-1 of 1,3-phenylenediamine in 0.1 M phosphate
buffer pH 6.9. The syringe is placed in a model 22 (Harvard Apparatus, Kent, United
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Kingdom) syringe pump.The flow-through cell is connected to the syringe and the wires
outside the tubing of the flow-through cell are connected to a model DECADE
electrochemical detector (Antec Leyden, Leiden, the Netherlands) by means of crocodile
clips. Electropolymerisation is performed at +0.8 V vs Ag/AgCl for one hour at a flow rate
of 0.5 µl.min-1 followed by electropolymerisation for an additional 30 minutes using the
monomer solution without the enzyme. Before storage and/or use, the biosensors are
rinsed with 0.1 M phosphate buffer pH 6.9 for 30 minutes at a flow rate of 0.5 µl.min-1. In
between, the flow-through biosensors thus produced are stored in the refrigerator at
4–8 ºC.
7.2.3 Testing of the flow-through biosensor by means of Flow Injection
Analysis
For the in vitro testing of the flow-through biosensor, measurements are carried out by
means of Flow Injection Analysis (FIA).The flow-through biosensor is connected to a VICI
Cheminert C4 valve (Valco Instruments, Houston, USA) and equipped with a 100 nanoliter
internal loop for sample injection.With the model 22 (Harvard Apparatus,Kent,GB) syringe
pump, carrier solution and sample is transported to the biosensor at a flow rate of 5 µl/min.
The internal loop of the valve is continuously filled with dialysate by connecting the
microdialysis probe and a home-made semi-vacuum syringe pump (1.2 ml monovette,
Sarstedt, Nümbrecht, Germany) as previously described34 each at a side of the VICI
Cheminert C4 valve. Dialysis is carried out at a flow rate of 300 nl.min-1 by means of under-
pressure.To avoid high dead volumes, connections between the various parts of the flow
injection analysis system are made with 150 µm OD x 50 µm ID fused silica capillary
(Aurora Borealis Control, Assen, the Netherlands). Injection and analysis of the sample is
carried out every two minutes. Detection is carried out at +0.5 V vs.Ag/AgCl by connecting
the wires outside the tubing of the flow-through cell to a model DECADE electrochemical
detector (Antec Leyden, Leiden, the Netherlands) by crocodile clips. Data is recorded on a
model BD 112 flatbed recorder (Kipp & Zonen, Delft, the Netherlands).
7.2.4 A lightweight measuring device for the continuous monitoring of
glucose
For the continuous monitoring of glucose during in vitro and in vivo experiments, a
lightweight measuring device (see figure 1) was constructed. One side of the flow-through
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biosensor is connected with the microdialysis probe whereas the other side is connected
with the semi-vacuum syringe pump (1.2 ml monovette, Sarstedt, Nümbrecht, Germany) as
previously described34. Low dead volume connections between the different parts of the
device are made with fused silica tubing (150 µm OD, 50 µm ID) (Aurora Borealis Control,
Assen, the Netherlands). Dialysate is sampled by means of under-pressure and is
continuously analysed by the flow-through biosensor at a flow rate of 300 nl.min-1.
Detection is carried out at +0.5 V vs. Ag/AgCl and data is collected with a model
DextralertTM (Analytic Devices, Zeist, the Netherlands) portable potentiostat.
7.2.5 Oral glucose tolerance test (OGTT)
OGTTs were performed with healthy young female subjects. All subjects gave their
informed consent and the study was approved by the Ethical Committee of the University
of Groningen. On day 1, a microdialysis probe is placed in one side of the umbilicus in the
subcutaneous fat tissue by means of a 16G catheter. At day 2, following an overnight fast,
subjects are monitored from 8.30 a.m. until 1 p.m.At 8 a.m. the implanted probe is washed
and de-aerated with sterile 0.9% NaCl solution. One end of the probe is connected to the
lightweight measuring device as described, whereas the other end of the probe is
connected to a buffer reservoir containing sterile PBS buffer (without Kathon CG). By
pulling the plunger of the semi-vacuum syringe pump a vacuum is created and sampling is
started.The dialysate thus obtained is continuously analysed for 5 hours at a flow rate of
300 nl.min-1.After reaching a steady state (mostly within 30 minutes), the subjects received
100 g of glucose dissolved in 200 ml of water via an oral administration. During the OGTTs,
blood samples were taken from a forearm vein cannula and analysed by the clinical
laboratory with an ECA 180 glucoanalyser (Medingen GmbH, Dresden, Germany). To
correct for the difference between glucose molarity (mol/l blood) of haemolysed whole
blood and molality (mol/kg water), the data obtained from the blood samples are multiplied
by 1.176 as prescribed by the manufacturer’s report. In this way a correct comparison can
be made between the content of glucose in blood versus dialysate.At the end of the study,
the subject is disconnected and the flow-through biosensor is coupled to the microdialysis
probe, which is placed in PBS buffer containing 5 mmol.l-1 of glucose for one-point
calibration.
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7.3 Results and discussion
7.3.1 Performance characteristics 
The determination of glucose is based upon the conversion of glucose by the immobilised
glucose oxidase (GOx) into the electrochemically detectable product, hydrogen peroxide.
To enable the efficient immobilisation of the enzyme and to improve the performance
characteristics of the final biosensor, we preferred a permselective membrane based upon
the electropolymerisation of the monomer 1,3-phenylenediamine in the presence of the
enzyme GOx. Accordingly, a substrate diffusion-limiting barrier is introduced which
prevents the reaction from following the intrinsic enzyme kinetics and as a consequence
extends the linear range. The linearity is investigated by analysing standard solutions of
glucose in the FIA and the continuous mode. For both modes a linearity of up to 30
mmol.l–1 of glucose is found.The signal/noise (S/N = 3) ratio indicates a limit of detection
of 0.5 mmol.l-1 in the FIA mode and 0.05 mmol.l-1 in the continuous mode.This means that
the linear range as well as the sensitivity of the biosensor is sufficient for the determination
of glucose levels in diabetic patients.The precision of several biosensors (n = 10) was tested
by analysing a standard solution of 5 mmol.l-1 of glucose in six-fold in the FIA mode.The
repeatability, expressed as the relative standard deviation in the peak height after six
consecutive injections was found to be 2-4% depending on the biosensor tested. To
investigate the selectivity of the biosensor regarding interference from electroactive
species, standard solutions, containing 0.1 mmol.l-1 ascorbic acid or 0.25 mmol.l-1 uric acid
in the presence of 0, 5 or 25 mmol.l-1 of glucose, are analysed in the continuous mode with
several (fresh and one week old) biosensors. No significant contribution to the signal is
observed and demonstrated the selectivity and stability of the permselective membrane.
Regarding the stability of the measuring device, it has to be emphasised that due to
electrode fouling by small endogenous proteins and the hydrogen peroxide mediated
enzyme inactivation, theoretically, in vivo measurements will not take longer than a couple
of days without re-calibration of the device. For this reason, it was decided to test the
stability of several flow-through biosensors by monitoring for only up to three days in the
continuous mode respectively a standard solution of 5 mmol.l-1 glucose and a dialysate of
serum sample containing approximately 6 mmol.l-1 glucose. It was observed that after an
initial decrease in sensitivity from 100% to approximately 70% within several hours of
practice, the biosensors remained their activity during the period tested. This is in
accordance with data reported by others35, who attributed this initial decline to leaching
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out of not fully immobilised enzyme and/or polymer film. Although more studies are
performed to evaluate the storage conditions and to increase the stability of the biosensors
in use and during storage, the biosensors are sufficiently stable for the purpose of this study.
To examine the accuracy of the measuring device, ex vivo studies have been conducted by
analysing serum samples obtained from the clinical laboratory for their content of glucose
in the FIA mode. By comparing the results with those obtained from the clinical laboratory
which have been analysed with validated methods, the accuracy of the measuring device is
determined. The results are presented as prescribed for methods of Self Monitoring of
Blood Glucose for patients with diabetes mellitus. For this reason the method presented
by Clarke et al36 was used. They described the error grid analysis, where the x-axis
represents the reference blood values and the y-axis the value generated by the measuring
device tested.The diagonal represents perfect agreements whereas data points above and
below the diagonal represent overestimates and underestimates. Based on the assumption
that the target blood glucose level ranges from 70 – 180 mg.dl-1, the grid is divided into five
regions of varying degrees of accuracy. In short, values found in zone A and B are clinically
acceptable, whereas values in zone C, D and E are potentially dangerous for patients and
are therefore clinically significant errors.As can be seen in figure 2, the results are well in
line with those obtained by the clinical laboratory; a correlation of Y = 0.98X + 0.19 with
a correlation coefficient of 0.99 for n = 54 was calculated. No results were found which
deviated more than 20% from the reference value. Based on these results, it was decided
to proceed with in vivo monitoring studies.
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Figure 2:
Error grid analysis for the
evaluation of clinical implications of
patient-generated blood glucose
values.The Y-axis represents the
values determined in the serum
samples by means of  the
biosensor; the X-axis represents the
values determined in the serum
samples by means of validated
clinical methods.
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7.3.2 The lightweight measuring device
Although numerous parameters determine the performance of the sampling by MD, in
general (near) quantitative recoveries are obtained at very low flow rates (less than 0.5
µl.min-1)28. To enable, however, real time on-line monitoring of the dialysate, the internal
volume of the measuring device has to be extremely small. By using tygon tubing with a
defined diameter, a flow-through cell with a defined volume can be easily constructed.With
an internal diameter of 0.005 inch (0.127 mm), the tubing has a specified volume of 127
nl.cm-1. If the electrodes are positioned within 1-2 mm of each other, a cell with a total
internal volume of 10-20 nanoliter is obtained. By connecting the flow-through cell with, for
instance, 4 cm of 50 µm ID x 150 µm OD fused silica tubing (with a specified volume of 20
nl.cm-1), the total internal volume of the measuring device is 100 nanoliter or less. This
means that at a flow rate of 300 nl.min-1, the delay time between sampling and analysis is
less than a minute. Because of the relatively large internal volume of the CMA 60 MD probe
however, a total delay time of approximately 2-3 minutes was found. Although this delay
time is one of the smallest reported for a MD based measuring device, in vivo correlation
studies will have to prove whether or not this delay time will be sufficiently low for
adequate and practical use of diabetic patients.
By using a semi-vacuum syringe pump, as described earlier in detail34, a stable flow rate of
300 nl.min-1 can be produced for up to several days3 without the need of (additional)
batteries. This means that the wet part of the measuring device outside the body
(biosensor, pump, fused silica and electrical connections and housing) weighs less then 5
gram, which is negligible, compared to the insulin pumps worn by many diabetic patients.
For detection and data collection, a portable potentiostat provided with internal data-
logging and rechargeable battery is used.The DextralertTM collects continuously data and
every minute the mean value of the sampled minute is filed in its internal memory. The
results can directly be recorded by connecting the DextralertTM to a flatbed recorder or
via the DextralertTM software program installed on a Windows95/98/NT PC. This first
prototype of the DextralertTM, with a weight of approximately 250 gram can be easily worn
by attaching the instrument to a belt with the provided clip.
7.3.3 Oral glucose tolerance test (OGTT)
To demonstrate the applicability of the lightweight measuring device described in this
article, the first set of results of our ongoing in vivo studies are presented. On the first day,
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a MD probe is placed in one side of the umbilicus in the subcutaneous fat tissue by means
of a 16G catheter. On the second day a fresh biosensor is connected to the implanted MD
probe after allowing to reach an equilibrium for 30 minutes. Dialysate is then continuously
analysed at a flow rate of 300 nl.min-1 as schematically demonstrated in figure 1. During the
OGTT blood samples are collected and analysed in the clinical laboratory on their content
of glucose. In figure 3, some typical data obtained during the OGTT on healthy volunteers
are demonstrated.The data presented are corrected for the delay time, which is found to
be several minutes. As can be seen in figure 3a, in one case the content of glucose in the
dialysate reasonably follows the blood glucose content. However, frequently we have
observed a lower glucose content in the dialysate (see figure 3a) compared to blood and a
relative low correlation was found (Y = 0.82, R2 = 0.56) (see figure 4a). Based upon the in
vitro and ex vivo performance characteristics of the measuring device, this phenomenon can
not (only) be attributed to the measuring device. We believe, as already suggested by
others37,38, that the values found in the interstitial fluid are influenced by the characters of
the tissue surrounding the probe.The present results are comparable with those obtained
during similar studies24 applying other (validated) analytical methods. For instance
Wientjes37 demonstrated increasing glucose recoveries in interstitial fluid until a plateau is
reached 6-9 days after placing the probe. Especially the (individual) change in recovery
during the first day was significant. This effect was explained by him that insertion of the
probe can cause trauma to cells and capillaries.As a consequence, no (fully) functional layer
of tissue surrounds the probe and limits diffusional glucose transport. The increase of
glucose recoveries during the days after implantation follows from repair of the tissue
microstructure around the probe. Tiessen et al24 also observed relatively low interstitial
glucose contents compared to blood glucose levels in fat tissue. He attributed this effect to
that, depending on the location of the MD probe, the diffusion path of glucose as well as
possible glucose uptake by the cells in the subcutaneous interstitium may differ. Although
the amount of data are in this stage too limited to draw conclusions concerning this
phenomenon, it seems worthwhile to investigate whether or not a better correlation is
obtained if the measuring device is calibrated by means of the glucose levels found in blood.
Especially during home-care, diabetic patients must be able to calibrate and control in a
simple way their measuring device. It has to be emphasised however that, in order to
improve the quality of life of diabetic patients excessive calibration should be avoided. For
this reason, the data from the sampled interstitium are recalculated on the first blood
glucose value only. The results are demonstrated in figure 3b and 4b, and as can be seen
from both figures a better correlation is found between the values in blood and dialysate
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Figure 3a and 3b:
Typical graphs obtained for in vivo monitoring of glucose during glucose tolerance
tests on respectively three healthy volunteers (a) calibration of biosensor in vitro and
(b) calibration of biosensor on the first blood glucose value measured.
Blood glucose concentrations in time (■), and subcutaneous glucose concentrations
in time measured by the biosensor after ultraslow microdialysis (◆).The arrow in the
figures indicates the oral administration of glucose.
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(Y = 1.06, R2 = 0.80). However, for several subjects a significant delay time is found in the
decrease of the dialysate glucose content compared to the decrease in the blood glucose
values (see figure 3b), and may lead to a potentially dangerous situation for the diabetic
patient.Although these typical data have been observed in earlier studies24, no explanation
has been given so far.
In order to investigate this phenomenon more thoroughly, more clinical studies will
therefore be necessary. For this reason and to investigate the possibilities of the measuring
device for the monitoring of glucose for a longer period of time, more clinical studies will
be carried out in the near future.These studies will be extended by the monitoring of both
healthy volunteers and diabetic patients.
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Figure 4a and 4b:
Correlation between glucose in dialysate measured with biosensor and blood glucose measured
in the clinical laboratory: (a) calibration of biosensor in vitro, and (b) calibration of biosensor on
the first blood glucose value measured.
a
b
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7.4 Conclusions
Our ultimate goal is to develop a measuring device, which reliably measures glucose for at
least several days without excessive and difficult calibration steps. In addition, if only
(disposable) parts of the measuring device outside the body have to be replaced after
defined moments without the need of hospital personnel, the quality of life of diabetic
patients can thus be improved. Here, a portable lightweight measuring device is presented,
which comprises a sampling unit (MD probe), a miniaturised flow-through biosensor and a
semi-vacuum pump.Thanks to the low perfusion rate, (near) quantitative in vivo recoveries
are established which circumvents excessive calibration normally used for microdialysis
based measuring devices. The performance characteristics (linearity, precision, accuracy,
selectivity and stability) which have been determined during in vitro and ex vivo studies,
justifies the application of this measuring device for the in vivo monitoring of glucose in
subcutaneous sampled interstitium of diabetic patients.
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